Hydromorphone Hydrochloride Oral Solution

DEFINITION

Hydromorphone Hydrochloride Oral Solution contains NLT 90.0% and NMT 110.0% of the labeled amount of hydromorphone hydrochloride (C₁₇H₁₉NO₃ · HCl). It may contain suitable preservatives.

IDENTIFICATION

• A. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.

ASSAY

PROCEDURE

Diluent: Phosphoric acid and water (1:1000) **Solution A:** 1.0 mg/mL of sodium 1-heptanesulfonate monohydrate in methanol and water (1:9). To each li-ter of this solution add 1.0 mL of triethylamine, and adjust with phosphoric acid to a pH of 2.5 ± 0.1 . Solution B: 1.0 mg/mL of sodium 1-heptanesulfonate monohydrate in methanol and water (1:1). To each liter of this solution add 1.0 mL of triethylamine, and adjust with phosphoric acid to a pH of 2.5 ± 0.1 . Mobile phase: See Table 1.

Table 1

| Time (min) | Solution A (%) | Solution B (%) | | | |
|---------------|-------------------|-------------------|--|--|--|
| 0 | 85 | 15 | | | |
| 24 | 5 | 95 | | | |
| 25 | 85 | 15 | | | |
| 30 | 85 | 15 | | | |

The Standard solution and Sample solution should be kept in a cool place, protected from light. Standard solution: 0.08 mg/mL of USP Hydromorphone Hydrochloride RS in Diluent Sample solution: Nominally 0.08 mg/mL of hydromorphone hydrochloride obtained by diluting a suitable volume of Oral Solution in Diluent Chromatographic system (See Chromatography (621), System Suitability.) Mode: LC Detector: UV 220 nm Column: 4.6-mm × 5-cm; 3.5-µm packing L1 Column temperature: 45° Flow rate: 1 mL/min Injection volume: 20 µL System suitability Sample: Standard solution Suitability requirements **Tailing factor:** NMT 1.5 for the hydromorphone peak Relative standard deviation: NMT 2.0% Analysis Samples: Standard solution and Sample solution Calculate the percentage of the labeled amount of

hydromorphone hydrochloride (C17H19NO3 · HCl) in the portion of Oral Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

= peak response from the Sample solution rυ

- = peak response from the Standard solution rs Cs = concentration of USP Hydromorphone
- Hydrochloride RS in the Standard solution (mg/mL)

Cu = nominal concentration of hydromorphone hydrochloride in the Sample solution (mg/mL)

Acceptance criteria: 90.0%–110.0%

IMPURITIES

• ORGANIC IMPURITIES Diluent, Solution A, and Solution B: Prepare as directed in the Assay.

Mobile phase: See Table 2.

Table 2

| Time (min) | Solution A (%) | Solution B (%) |
|---------------|-------------------|-------------------|
| 0 | 94 | 6 |
| 25 | 94 | 6 |
| 40 | 20 | 80 |
| 70 | 20 | 80 |
| 75 | 94 | 6 |
| 90 | 94 | 6 |

The System suitability solution, Quantitation limit solu-tion, Standard solution, and Sample solution should be kept in a cool place, protected from light.

System suitability solution: 0.8 mg/mL of USP Hydromorphone Hydrochloride RS and 0.8 µg/mL of USP Hydromorphone Related Compound A RS in Diluent

Quantitation limit solution: 0.4 µg/mL of USP Hydromorphone Hydrochloride RS in Diluent **Standard solution:** 4 µg/mL of USP Hydromorphone Hydrochloride RS in Diluent

- Sample solution: Nominally 0.4 mg/mL of hydromorphone hydrochloride in Diluent
- Chromatographic system

(See Chromatography (621), System Suitability.) Mode: LC

Detector: UV 220 nm

Column: 3.9-mm \times 15-cm; 5- μ m packing L1 Column temperature: 45°

Flow rate: 1 mL/min

Injection volume: 20 µL

System suitability

Samples: System suitability solution, Quantitation limit solution, and Standard solution

Suitability requirements Resolution: NLT 1.0 between the hydromorphone related compound A and hydromorphone peaks, System suitability solution

Signal-to-noise ratio: NLT 10:1, Quantitation limit solution

Tailing factor: NMT 1.5 for the hydromorphone peak, Standard solution Relative standard deviation: NMT 5.0%, Standard

solution

Analysis

Samples: Diluent, Standard solution, and Sample solution

Calculate the percentage of any specified or unspecified degradation product in the portion of Oral Solution taken:

 $\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$

- = peak response for each degradation product rυ found, including those in Table 3, from the Sample solution
- = peak response of hydromorphone from the rs Standard solution

Hydromorphone 1

2 Hydromorphone

- C_s = concentration of USP Hydromorphone Hydrochloride RS in the *Standard solution* (mg/mL)
- C_U = nominal concentration of hydromorphone hydrochloride in the Sample solution (mg/mL)
- F = relative response factor for the corresponding individual specified or unspecified impurity (see Table 3)

Calculate the total degradation products by summing the percentage of all individual specified and unspecified degradation products determined to be at a level of 0.1% or greater, excluding the known process impurities, as indicated in *Table 3*.

Acceptance criteria: See *Table 3*. Disregard peaks corresponding to those from the *Diluent*, peaks that elute before a relative retention time of about 0.50, except for any peak with a relative retention time of about 0.34, and peaks that elute at the relative retention times of the process-related substances designated in *Table 3*.

| Table 3 | |
|---------|--|
|---------|--|

| Name | Relative Retention Time | Relative Response Factor | Acceptance Criteria, NMT (%) |
|--------------------------------------------------------------|-------------------------------|--------------------------------|------------------------------------|
| Specified and un- identified degrada- tion product | 0.34 | 1.0 | 0.2 |
| 8-Hydroxy- hydromorphone ^{a,b} | 0.50 | _ | — |
| Dihydromorphine (DHM) ^{a,c} | 0.61 | _ | _ |
| Morphine ^{a,d} | 0.65 | _ | _ |
| Hydromorphone N- oxide ^{e,f} | 0.79 | 0.87 | 0.2 |
| Hydromorphone | 1.0 | _ | — |
| 2,2'-Bis- hydromorphone dihydrochloride ^{e,g} | 2.02 | 1.7 | 0.2 |
| Individual unspecified degradation prod- ucts | _ | 1.0 | 0.2 |
| Total degradation products | | | 1.0 |

^a Process impurity.

^b 4,5α-Epoxy-17-methylmorphinan-3,8-diol-6-one.

^c 4,5α-Epoxy-17-methylmorphinan-3,6α-diol.

^d 7,8-Didehydro-4,5α-epoxy-17-methylmorphinan-3,6α-diol.

e Degradation product.

^f 4,5α-Epoxy-3-hydroxy-17-methylmorphinan-6-one *N*-oxide.

g 2,2'-Bihydromorphone.

SPECIFIC TESTS

• MICROBIAL ENUMERATION TESTS (61) and TESTS FOR SPECI-FIED MICROORGANISMS (62): The total aerobic microbial count does not exceed 10² cfu/mL, and the total yeasts and molds count does not exceed 10 cfu/mL. It meets the requirements of the test for the absence of *Escherichia coli*.

Change to read:

• **PH** (**791**): •3.5• (RB 1-Aug-2013)-6.5

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers, protected from light. Store at 25°, excursions permitted between 15° and 30°.
- **LABELING:** Identify in the product labeling any preservative used in the Oral Solution.

Change to read:

• USP REFERENCE STANDARDS $\langle 11 \rangle$

USP Hydromorphone Hydrochloride RS USP Hydromorphone Related Compound A RS •7,8-Didehydro-4,5α-epoxy-3-hydroxy-17-methylmorphinan-6-one hydrochloride. C₁₇H₁₇NO₃ 319.78 (RB 1-Aug-2013)